Published in Gene Therapy Weekly, February 1st, 2001
"Gene transfer into vsmcs holds promise for studying the pathogenesis of arterial disorders," stated L.M. Akyurek and colleagues from the U.S. National Institutes of Health, Bethesda, Maryland. "However, a potential limitation of vectors with heterologous promoters is organ toxicity resulting from unrestricted transgene expression. Vascular smooth muscle cell-specific gene expression could increase the safety of vectors for vascular diseases."
Akyurek et al. published the results of their study in the journal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.